LeMaitre Vascular (LMAT)'s Technical Outlook is Bright After Key Golden Cross

After reaching an important support level, LeMaitre Vascular, Inc. (LMAT) could be a good stock pick from a technical perspective. LMAT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Zacks Investment Research • Mar 2, 2026

LeMaitre to Participate at Upcoming Investor Conferences in March

BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March.

GlobeNewsWire • Feb 27, 2026

LeMaitre Vascular: The Compounder Keeps Compounding

LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft's international rollout exceeded expectations, with 2025 sales doubling guidance and a projected $10M in 2026. This could drive earnings growth for years to come. LMAT maintains a robust $190M net cash position and recently increased its dividend by 25%. The board has also authorized a $100M share repurchase program.

Seeking Alpha • Feb 27, 2026

LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

LeMaitre Q4 2025 Financial Results

BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance.

GlobeNewsWire • Feb 25, 2026

LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026

BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.

GlobeNewsWire • Feb 11, 2026

4 Stocks With High Coverage Ratios Offer Safer Bets Going Into 2026

High coverage ratios and earnings growth make CAH, LTH, LMAT and FLS safer investment bets heading into 2026.

Zacks Investment Research • Dec 1, 2025

Here is Why Growth Investors Should Buy LeMaitre (LMAT) Now

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • Nov 27, 2025

New Strong Buy Stocks for November 14th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

Zacks Investment Research • Nov 14, 2025

LeMaitre to Participate in Upcoming Investor Conferences

BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.

GlobeNewsWire • Nov 12, 2025